Akèy › Kasinom Selil Transizyonèl (Urotelyal) › Illinois › Chicago
Etid klinik pou Kasinom Selil Transizyonèl (Urotelyal) nan Chicago, IL
14 etid pou Kasinom Selil Transizyonèl (Urotelyal) ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #26, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Ap rekriteFaz 3
- University of Illinois, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Ap rekriteEtid obsèvasyon
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Ap rekriteFaz 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Ap rekriteFaz 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Ap rekriteFaz 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Ap rekriteEtid obsèvasyon
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Ap rekriteFaz 2
- Northwestern University, Chicago
Etid Kasinom Selil Transizyonèl (Urotelyal) nan lòt vil
- Nashville, TN23 etid
- New York City, NY22 etid
- Dallas, TX18 etid
- Edison, NJ18 etid
- Houston, TX18 etid
- Los Angeles, CA17 etid
- Queens, NY15 etid
- Arlington, VA12 etid
- San Antonio, TX11 etid
- Boston, MA11 etid
- Austin, TX10 etid
- Orange, CA10 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.